Roger Dansey Net Worth

The estimated Net Worth of Roger D Dansey is at least $29.9 Million dollars as of 15 May 2024. Mr. Dansey owns over 2,166 units of Seagen Inc stock worth over $1,544,576 and over the last 6 years he sold SGEN stock worth over $21,608,159. In addition, he makes $6,718,820 as Chief Medical Officer at Seagen Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Dansey SGEN stock SEC Form 4 insiders trading

Roger has made over 41 trades of the Seagen Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 2,166 units of SGEN stock worth $495,711 on 15 May 2024.

The largest trade he's ever made was selling 34,635 units of Seagen Inc stock on 28 June 2022 worth over $6,234,300. On average, Roger trades about 4,738 units every 31 days since 2018. As of 15 May 2024 he still owns at least 6,749 units of Seagen Inc stock.

You can see the complete history of Mr. Dansey stock trades at the bottom of the page.

Roger Dansey biography

Roger Dansey serves as Chief Medical Officer of the Company. Prior to that, Dr. Dansey served as Senior Vice President, Clinical Oncology Research at Merck & Co. from January 2015 through April 2018. While at Merck, Dr. Dansey was Therapeutic Area Head for Late Stage Oncology and was responsible for the ongoing registration efforts for KEYTRUDA® (pembrolizumab) across multiple tumor types. Prior to Merck, from August 2013 to December 2014, Dr. Dansey served as the Vice President, Oncology Clinical Research at Gilead Sciences, Inc. Dr. Dansey previously worked at Amgen in roles of increasing responsibility in Amgen’s oncology and hematology therapeutic areas, including as the Global Development Leader for XGEVA®. Dr. Dansey received his Medical Degrees from the University of Witwatersrand, Johannesburg, South Africa.

What is the salary of Roger Dansey?

As the Chief Medical Officer of Seagen Inc, the total compensation of Roger Dansey at Seagen Inc is $6,718,820. There are 1 executives at Seagen Inc getting paid more, with Clay Siegall having the highest compensation of $14,521,500.

How old is Roger Dansey?

Roger Dansey is 63, he's been the Chief Medical Officer of Seagen Inc since 2018. There are 3 older and 17 younger executives at Seagen Inc. The oldest executive at Seagen Inc is Marc Lippman, 75, who is the Independent Director.

Insiders trading at Seagen Inc

Over the last 22 years, insiders at Seagen Inc have traded over $729,924,224 worth of Seagen Inc stock and bought 35,347,908 units worth $1,433,871,526 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Felixbaker Julian Baker Bro..., and Brothers Life Sciences Capi.... On average, Seagen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $18,157,295. The most recent stock trade was executed by David R Epstein on 10 November 2023, trading 10,620 units of SGEN stock currently worth $2,262,166.

What does Seagen Inc do?

seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys

Complete history of Mr. Dansey stock trades at Inovio Pharmaceuticals Inc, Seagen Inc, and Kronos Bio

Seagen Inc executives and stock owners

Seagen Inc executives and other stock owners filed with the SEC include:

• Clay Siegall,
  Chairman of the Board, President, Chief Executive Officer
• Roger Dansey,
  Chief Medical Officer
• Todd Simpson,
  Chief Financial Officer
• Jean Liu,
  Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary
• Vaughn Himes,
  Chief Technical Officer
• Dr. Clay B. Siegall,
  Co-Founder, Chairman, Pres & CEO
• Dr. Roger D. Dansey M.D.,
  Chief Medical Officer & Interim CEO
• Jean I. Liu,
  Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec.
• Jean I. Liu J.D., M.S.,
  Chief Legal Officer
• Charles R. Romp,
  Exec. VP of Commercial U.S.
• Todd E. Simpson,
  Chief Financial Officer
• Felix Baker,
  Lead Independent Director
• David Gryska,
  Independent Director
• John Orwin,
  Independent Director
• Nancy Simonian,
  Independent Director
• Alpna Seth,
  Independent Director
• Daniel Welch,
  Independent Director
• Marc Lippman,
  Independent Director
• Ted Love,
  Director
• David Caouette,
  VP of Corp. Communications
• Dr. Vaughn B. Himes,
  Chief Technical Officer
• Christopher P. Pawlowicz,
  Exec. VP of HR
• Matt Skelton,
  VP of Marketing
• Natasha A. Hernday,
  Exec. VP of Corp. Devel. & Alliance Management
• Nancy Whiting B.Sc., Pharm.D.,
  Exec. VP of Corp. Strategy, Alliances & Communications
• Peggy Pinkston,
  VP of Investor Relations
• Bros. Advisors Lp Baker Bro...,
  
• Bros. Advisors Lp Baker Bro...,
  
• Felixbaker Julian Baker Bro...,
  
• Srinivas Akkaraju,
  Director
• Eric Dobmeier,
  Vice President,
• Bros. Advisors Lp667, L.P.B...,
  
• Sandra M Swain,
  
• Morgan Partners Bhca Lpjpmp...,
  
• / Tisch Capital (Gp), Llcba...,
  
• Biotech Capital (Gp), Llcba...,
  
• Robin G Taylor,
  Chief Commercial Officer
• Felix667, L.P.Baker Julian ...,
  
• John Peter Mclaughlin,
  Director
• Felix Baker,
  Director
• Morris Rosenberg,
  SVP, Development
• Bruce J. Seeley,
  EVP, Commerical
• Felix667, L.P.Baker Brother...,
  
• Thomas C Reynolds,
  Chief Medical Officer
• Christopher S. Boerner,
  SVP, Commercial
• Brothers Life Sciences Capi...,
  
• Capital (Gp), Llcbaker Juli...,
  
• Holdings, Inc.H&Q Employee ...,
  
• Bros. Capital (Gp), Llcbake...,
  
• Bros. Advisors Lp667, L.P.B...,
  
• Darren S Cline,
  SVP, Commercial
• Morgan Partners Bhca Lpjpmp...,
  
• Felixbaker Julian Baker Bro...,
  
• Franklin M Berger,
  Director
• Morgan Partners Bhca Lp Jp,
  10% owner
• Daniel Floyd Jr Hoth,
  Director
• Morgan Partners Bhca Lpjpmp...,
  
• Morgan Partners Bhca Lpjpmp...,
  
• Jonathan Gallen,
  10% owner
• Management Partners Vi Llcd...,
  
• Pamela A Trail Smith,
  Chief Scientific Officer
• Brothers Life Sciences Capi...,
  
• Biotech Capital Ii Gp Llcba...,
  
• Morgan Partners Bhca Lpjpmp...,
  
• Morgan Partners Bhca Lpjpmp...,
  
• Biotech Capital Ii (Z) (Gp)...,
  
• Amy Sing,
  Sr. Director Medical Affairs
• Michael Powell,
  Director
• Biotech Capital Iii (Z) (Gp...,
  
• Tim Carroll,
  CFO
• Investment Llc Cascade,
  
• Douglas Southern,
  Director
• Karl Erik Hellstrom,
  Director
• Michael Mcdonald,
  Chief Medical Officer
• Morgan Partners Bhca Lpjpmp...,
  
• Peter Senter,
  Vice President, Chemistry
• H Perry Fell,
  Chairman
• Bros. Advisors Lp Baker Bro...,
  
• Bros. Advisors Lp667, L.P.B...,
  
• David R Epstein,
  CEO
• Charles R Romp,
  EVP, Commercial U.S.